Residents and Fellows Research in Progress
Tuesday, November 14, 2023
08:30 AM–10:00 AM
Abstract
Introduction:
Vancomycin is the mainstay of parenteral therapy for Methicillin-resistant Staphylococcus aureus (MRSA) pneumonia. Current Infectious Diseases Society of America (IDSA) guidelines recommend intravenous vancomycin or oral/intravenous linezolid for treating MRSA pneumonia. However, previous studies have demonstrated that linezolid could have favorable outcomes compared to vancomycin as its high drug acquisition costs are offset by lower treatment failure-related costs and fewer days of hospitalization.
Research Question or Hypothesis:
The use of linezolid for MRSA pneumonia decreases overall pharmacy costs and improves patient outcomes when compared to standard vancomycin therapy.
Study Design:
This study is a single-center retrospective review of hospitalized adult patients who received linezolid or vancomycin for confirmed MRSA pneumonia at CHRISTUS Mother Frances Hospital – Tyler (CMFH) from June 1, 2022, to July 31, 2023.
Methods:
This review will include adult patients with a confirmed MRSA pneumonia diagnosis who received treatment within 48 hours of admission between June 1, 2022, and July 31, 2023. Patients who are pregnant, received other anti-MRSA antibiotics, or received both linezolid and vancomycin during their admission will be excluded from the review. The primary outcome will include the cost of the regimen in U.S. dollars, which will be adjusted for the acquisition cost of the selected drug and the cost of laboratory monitoring. Secondary outcomes will include hospital length of stay, treatment duration, and all-cause mortality. Adverse effects will be evaluated including the trough or area under the curve/minimum inhibitory concentration (AUC/MIC) trend within the first 10 days of therapy to assess for accumulation and the incidence of nephrotoxicity with the use of vancomycin, and the incidence of thrombocytopenia with linezolid. Data will be obtained via manual chart review and dispensing reports in the electronic medical record. This data will be analyzed using descriptive statistics, t-tests and chi-squared as appropriate.
Results:
To be presented
Conclusion:
To be presented
Presenting Author
Nicole Anne Javier PharmDCHRISTUS Trinity Mother Frances - Tyler
Authors
Corey Cicci PharmD, BCPS, BCEMP
CHRISTUS Trinity Mother Frances Health System
Craig Cocchio PharmD, BCPS, DABAT
Christus Trinity Mother Frances
Britany Trejo PharmD
CHRISTUS Mother Frances Hospital